Member Info for Basser1

Yes there are several potential scenarios for SRA 737. I have no idea how much a sell on would bring in but let’s just say 200 Million as an example. That would give Sierra. 470 Million - perhaps enough to buy a new immunotherapy molecule and take it into clinical trials - after all Sierra has plenty of experience in running trials. My view is that they are more likely to continue the SRA 737 trials given that they have taken it through Stages1/2 and they may be able to fast track Anogenital through stage 3. There may be some money left to look at a Combo with Parp given the scientific evidence over the last two years. But until an announcement it’s all pure conjecture.

Krone - 150 Mill dollars raise is a lot when Sierra already have 120 million dollars in bank. It can’t all be for Momelotinib so does it Indicate that Sierra will take forward SRA 737 alone or in partnership?
Or Perhaps has Sierra got its eye on purchasing something else?

Loopylo- Think it was circulated over a week ago, but well worth a repost to reinforce the potential of Sareums new generation molecule in new treatments for Lupus, Psoriasis and Rheumatoid Arthritis.

The Mixed Shelf action for 150mill dollars doesn’t seem to have done any damage to the Sierra Share price - up 7.2 percent today. The SRA737 data must be good. Let’s see if the share price continues to rise next week. Look forward to seeing the Phase1/2 trial results and plans to extend the clinical trials.

This is great news for Sareum.
Should we expect a Sierra/ Gilead partnership to take forward a fast tracked anogentital Trial as well as trials re the promising combo of SRA 737 and Parp inhibitor in treatment of Small Cell Lung Cancer, Ovarian and Prostate Cancer?

So as expected the Q-10 told us nothing that we didn’t already know. What was interesting was the news that SRA141 had been licensed back to its original owner. Beginning to think that this will go back to CRUK as they are fans of SRA 737 and hopefully they will be able to take forward the very promising research re Small Cell Lung Cancer, Ovarian and Prostate Cancers as well as Anogenital Cancer.

Do us a favour and stop continuously talking about RNS’s!

Top of page 6
The company profile also includes SRA737 a potent highly Selective orally biovailable CHK1 inhibitor a promising target for the treatment of cancer. The company is currently focusing on Momelotinib and is exploring options to support the future continued development of SRA737.

Don’t know but here is some background. Interestingly SAR gets a mention.
BMS to disclose TYK2 inhibitor data that backed Phase III move for psoriasis 1

Three x £1million Delayed Share purchases. Buyer or buyers still accumulating by look of it.

RMM yes, meant the Sierra share price and sale of SRA 737. My fault not written clearly!

If there is any news to come out on SRA 737 in or with the Sierra 10-Q, I would expect to see a rise in the share price beforehand.

Apologies just noticed I could not see the first 2 hours of trading!

Usual story today with buys swamping the sells and we are down. Not that it matters as the trading volume (16million) was way below levels seen last week. Easier for MMs to drop the price and hope for some cheaper shares. Most Invested being patient here and are sitting tight waiting for the first strand of news to come through. GLA

The World Health Organisation stated today that while hopes for a vaccine are strong we may never have a silver bullet for Coronovirus. Thus the need for alternative treatments for hospitalised patients. Bring on SDC- 1801!

Especially as he was due to be in office tomorrow.

Thoth- with all that’s going on at the moment, wouldn’t think its time to go on holiday? But you never know.

The momentum gained over the last month or so has been a game changer for Sareum. It has spawned a big increase in publicity about the potential of the company’s assets. This bulletin Board had for far too long been the key mouthpiece in trying to get awareness out to a wider community- backing that up with good research evidence. We will not be going backwards from here on in. There will be news on all of the company’s main assets between now and the end of the year but lets not forget that you cannot rush great science so we should do our best to be patient - we will get news when the company or market thinks it is the right time. Expecting and predicting an RNS every week is counter productive and can undermine confidence day by day. We know news is coming on a number of fronts so let’s sit back, be patient and enjoy the ride! GLA

You never know. Might be using Zoom - no end to end encryption apparently.

Good interview further demonstrating SRA 737 potential. Video was early March and Tim said trial would continue for a month or so? Progress report well overdue.